Pre-market most active: ALNEV.PA Neovacs S.A. (EURONEXT) up 6.25% 20 Feb 2026

ALNEV.PA stock is trading in pre-market at €0.0017, up 6.25%, as heavy activity pushes volume to 29,623,724 shares. Neovacs S.A. (ALNEV.PA) on EURONEXT is one of Europe’s most active small-cap biotech tickers this session. The move follows thin liquidity, a large relative volume of 3.55, and persistent investor attention to its Kinoid pipeline and cash metrics. Traders should note the extreme price history and high volatility in the healthcare biotechnology sector.

Pre-market snapshot and why ALNEV.PA stock is most active

Today ALNEV.PA stock opened at €0.0017 and printed a day high of €0.0017 and a day low of €0.0014. Volume is 29,623,724, versus an average of 8,352,585, giving a relative volume of 3.55. This high turnover explains the “most active” listing despite a market cap of €810.00.

One clear driver is extremely shallow order books. Small share counts and tight float can create outsized percentage moves on modest orders, which we observe in the current pre-market session.

Fundamentals and valuation for ALNEV.PA stock

Neovacs S.A. (ALNEV.PA) operates in biotechnology with a focus on therapeutic vaccines. Trailing EPS is -221.36 and the company reports no meaningful PE multiple. Book value per share is listed as 103.50 (TTM) but price-to-book is near zero given the micro price, reflecting extreme mismatch between accounting per-share figures and traded price.

Current ratios and cash metrics show stresses: cash per share 2.50 (TTM) and operating cash flow per share -20.64. These signal ongoing funding needs common for small biotech developers and justify close attention to dilution risk.

Technicals, liquidity and trading indicators for ALNEV.PA stock

Momentum indicators show ALNEV.PA stock as deeply oversold with RSI 12.15 and Stochastic %K 7.23. On-chain OBV is negative and the price averages are depressed: 50-day €0.00642 and 200-day €1.02, highlighting long-term decline and recent micro-price trading.

The relative volume spike and ATR near zero reflect micro-price reporting; traders face high slippage and wide effective spreads. Use limit orders and small size when trading this ticker on EURONEXT.

Meyka AI grade and ALNEV.PA stock forecast

Meyka AI rates ALNEV.PA with a score out of 100: 62.65 / 100 (Grade B) – HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are informational and not financial advice.

Meyka AI’s forecast model projects a near-term base-case target of €0.0050. Compared with the current price €0.0017, that implies an upside of 194.12%. A conservative downside scenario to €0.0005 implies -70.59%. Forecasts are model-based projections and not guarantees.

Sector context, catalysts and risks for ALNEV.PA stock

Neovacs sits in Healthcare – Biotechnology, a sector with average ROE near 6.00% and typical R&D-driven valuation swings. Positive clinical updates or partner deals can spike interest, while failed trials or cash shortfalls drive sharp declines.

Key risks: continued negative EPS, thin liquidity, potential dilution, and long gaps between earnings/events. Catalysts to watch include Phase IIb results, licensing deals, and cash raises announced on EURONEXT.

Final Thoughts

ALNEV.PA stock is an ultra-high-volatility micro-cap on EURONEXT trading at €0.0017 pre-market with 29.62M shares changing hands. The stock’s trading profile is driven by shallow liquidity, biotech pipeline news sensitivity, and a stretched fundamental picture: EPS -221.36, operating cash flow per share -20.64 and market cap €810.00. Meyka AI’s forecast model projects a near-term base-case target of €0.0050, implying 194.12% upside versus today’s price, while a downside stress target of €0.0005 shows -70.59% risk. Traders attracted by the “most active” label should size positions very small, prefer limit orders, and monitor corporate updates. For further real-time quotes and peer comparisons, see the Neovacs page on Meyka AI and recent market comparisons on Investing.com. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.